Financials in USD. Standardized financial statements.
A compact view of how Sorrento Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $62.84M | $52.90M | $39.99M | $31.43M | $21.19M | $151.86M | $8.15M | $4.59M | $3.83M | $460,148 |
| Revenue Growth? | +18.8% | +32.3% | +27.2% | +48.3% | -86.0% | +1762.8% | +77.6% | +20.0% | +731.3% | 0.0% |
| Cost of Revenue? | $33.45M | $13.03M | $9.94M | $12.24M | $10.07M | $11.03M | $3.70M | $1.95M | $2.04M | $4,440 |
| Gross Profit? | $29.39M | $39.87M | $30.05M | $19.20M | $11.12M | $140.83M | $4.46M | $2.64M | $1.78M | $455,708 |
| Gross Margin? | +46.8% | +75.4% | +75.1% | +61.1% | +52.5% | +92.7% | +54.7% | +57.5% | +46.6% | +99.0% |
| Operating Expenses? | $533.70M | $407.92M | $231.57M | $214.38M | $140.60M | $88.49M | $64.35M | $52.63M | $36.31M | $16.14M |
| Operating Income? | -$504.31M | -$368.05M | -$201.53M | -$195.18M | -$129.48M | $52.34M | -$59.90M | -$74.00M | -$34.74M | -$21.67M |
| EBITDA? | -$539.93M | -$435.99M | -$275.69M | -$308.39M | -$147.10M | $27.38M | -$60.34M | -$9.74M | -$31.55M | -$20.37M |
| Income Before Tax | -$561.75M | -$462.53M | -$316.42M | -$359.58M | -$213.78M | $15.31M | -$64.83M | -$13.76M | -$36.36M | -$21.91M |
| Income Tax Expense | -$2.42M | -$33.52M | -$2.01M | -$473,000 | -$6.27M | -$36.04M | -$896,000 | $36.31M | -$1.70M | $9,615 |
| Net Income? | -$572.84M | -$429.01M | -$298.46M | -$359.10M | -$203.54M | $9.06M | -$60.92M | -$45.81M | -$34.66M | -$21.91M |
| EPS? | $-1.37 | $-1.46 | $-1.30 | $-2.56 | $-1.92 | $0.13 | $-1.21 | $-1.24 | $-1.30 | $-1.46 |
| Diluted EPS? | $-1.37 | $-1.46 | $-1.30 | $-2.56 | $-1.92 | $0.13 | $-1.21 | $-1.24 | $-1.30 | $-1.46 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality